Loading...

GeNeuro

DB:GEM
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GEM
DB
€61M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurological disorders and autoimmune diseases. The last earnings update was 216 days ago. More info.


Add to Portfolio Compare Print
  • GeNeuro has significant price volatility in the past 3 months.
GEM Share Price and Events
7 Day Returns
0.7%
DB:GEM
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-32.2%
DB:GEM
-7.4%
DE Biotechs
-5.6%
DE Market
GEM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GeNeuro (GEM) 0.7% -1.2% 33.9% -32.2% -61.2% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • GEM underperformed the Biotechs industry which returned -7.4% over the past year.
  • GEM underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
GEM
Industry
5yr Volatility vs Market

Value

 Is GeNeuro undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of GeNeuro to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for GeNeuro.

DB:GEM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GEM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 18%) (0.3%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:GEM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for GeNeuro is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:GEM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.01%)
2019 44.00 Analyst x1 40.74
2020 -14.65 Analyst x2 -12.56
2021 -19.50 Analyst x1 -15.48
2022 -20.00 Analyst x1 -14.69
2023 69.40 Analyst x1 47.21
2024 109.05 Est @ 57.14% 68.68
2025 152.75 Est @ 40.06% 89.06
2026 195.69 Est @ 28.11% 105.64
2027 234.33 Est @ 19.75% 117.12
2028 266.88 Est @ 13.89% 123.50
Present value of next 10 years cash flows €549.22
DB:GEM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €266.88 × (1 + 0.23%) ÷ (8.01% – 0.23%)
€3,436.98
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €3,436.98 ÷ (1 + 8.01%)10
€1,590.39
DB:GEM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €549.22 + €1,590.39
€2,139.61
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €2,139.61 / 14.59
€146.66
DB:GEM Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GEM represents 0.99045x of ENXTPA:GNRO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99045x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 146.66 x 0.99045
€145.26
Value per share (EUR) From above. €145.26
Current discount Discount to share price of €4.15
= -1 x (€4.15 - €145.26) / €145.26
97.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price GeNeuro is available for.
Intrinsic value
>50%
Share price is €4.15 vs Future cash flow value of €145.26
Current Discount Checks
For GeNeuro to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • GeNeuro's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • GeNeuro's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GeNeuro's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GeNeuro's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GEM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.01
ENXTPA:GNRO Share Price ** ENXTPA (2019-04-24) in EUR €4.19
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GeNeuro.

DB:GEM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:GNRO Share Price ÷ EPS (both in EUR)

= 4.19 ÷ -0.01

-318.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GeNeuro is loss making, we can't compare its value to the Europe Biotechs industry average.
  • GeNeuro is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does GeNeuro's expected growth come at a high price?
Raw Data
DB:GEM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -318.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
33.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GeNeuro, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GeNeuro's assets?
Raw Data
DB:GEM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.76
ENXTPA:GNRO Share Price * ENXTPA (2019-04-24) in EUR €4.19
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:GEM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:GNRO Share Price ÷ Book Value per Share (both in EUR)

= 4.19 ÷ 0.76

5.51x

* Primary Listing of GeNeuro.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GeNeuro is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess GeNeuro's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. GeNeuro has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is GeNeuro expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
33.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GeNeuro expected to grow at an attractive rate?
  • GeNeuro's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • GeNeuro's earnings growth is expected to exceed the Germany market average.
  • GeNeuro's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GEM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GEM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 33.5%
DB:GEM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 18.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GEM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GEM Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 106 70 1
2022-12-31 21 -20 1
2021-12-31 21 -19 1
2020-12-31 11 -14 2
2019-12-31 79 -14 1
2018-12-31 24 -1 2
DB:GEM Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 19 -6 0
2018-03-31 17 -7 -3
2017-12-31 15 -8 -6
2017-09-30 10 -13 -11
2017-06-30 6 -19 -16
2017-03-31 6 -16 -15
2016-12-31 6 -14 -14
2016-09-30 6 -4 -11
2016-06-30 5 6 -9
2016-03-31 4 9 -7
2015-12-31 3 12 -4
2015-09-30 5 8 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • GeNeuro's earnings are expected to grow significantly at over 20% yearly.
  • GeNeuro's revenue is expected to grow by 18.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GEM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from GeNeuro Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GEM Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.77 4.77 4.77 1.00
2022-12-31
2021-12-31
2020-12-31 -0.98 -0.98 -0.98 1.00
2019-12-31 -0.96 -0.96 -0.96 1.00
2018-12-31 -0.04 -0.04 -0.04 1.00
DB:GEM Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.01
2018-03-31 -0.21
2017-12-31 -0.40
2017-09-30 -0.75
2017-06-30 -1.11
2017-03-31 -1.06
2016-12-31 -1.02
2016-09-30 -0.86
2016-06-30 -0.69
2016-03-31 -0.54
2015-12-31 -0.37
2015-09-30 -0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GeNeuro will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess GeNeuro's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GeNeuro has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has GeNeuro performed over the past 5 years?

  • GeNeuro's last earnings update was 216 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GeNeuro's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GeNeuro does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare GeNeuro's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare GeNeuro's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
GeNeuro's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GeNeuro Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GEM Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 19.02 -0.19 4.67 14.59
2018-03-31 16.98 -3.01 4.76 15.22
2017-12-31 14.95 -5.84 4.85 15.85
2017-09-30 10.36 -11.01 4.01 16.34
2017-06-30 5.76 -16.18 3.18 16.83
2017-03-31 5.84 -15.14 3.50 15.54
2016-12-31 5.92 -14.10 3.83 14.25
2016-09-30 5.68 -11.41 4.25 11.81
2016-06-30 5.45 -8.71 4.68 9.38
2016-03-31 3.99 -6.60 3.32 7.12
2015-12-31 2.54 -4.49 1.97 4.87
2015-09-30 5.18 -1.26 1.81 4.18
2015-06-30 7.81 1.96 1.65 3.49
2015-03-31 7.56 1.87 1.56 3.54
2014-12-31 7.31 1.78 1.48 3.60
2013-12-31 0.02 -3.50 0.75 2.61
2012-12-31 0.01 -3.52 0.67 2.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if GeNeuro has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if GeNeuro has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if GeNeuro improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess GeNeuro's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GeNeuro has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is GeNeuro's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GeNeuro's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GeNeuro is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • GeNeuro's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GeNeuro's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 108.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GeNeuro Company Filings, last reported 9 months ago.

DB:GEM Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 11.09 0.18 17.32
2018-03-31 11.09 0.18 17.32
2017-12-31 13.06 0.18 26.60
2017-09-30 13.06 0.18 26.60
2017-06-30 10.68 0.22 23.10
2017-03-31 10.68 0.22 23.10
2016-12-31 18.67 0.18 34.49
2016-09-30 18.67 0.18 34.49
2016-06-30 25.65 0.18 42.41
2016-03-31 25.65 0.18 42.41
2015-12-31 1.69 0.18 19.56
2015-09-30 1.69 0.18 19.56
2015-06-30 4.55 0.17 7.02
2015-03-31 4.55 0.17 7.02
2014-12-31 6.24 0.17 7.86
2013-12-31 2.71 0.49 3.18
2012-12-31 -0.06 3.86 3.93
  • GeNeuro's level of debt (1.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (165% vs 1.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • GeNeuro has sufficient cash runway for more than 3 years based on current free cash flow.
  • GeNeuro has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 74.8% each year.
X
Financial health checks
We assess GeNeuro's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GeNeuro has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is GeNeuro's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from GeNeuro dividends. Estimated to be 0% next year.
If you bought €2,000 of GeNeuro shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate GeNeuro's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate GeNeuro's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GEM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GEM Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as GeNeuro has not reported any payouts.
  • Unable to verify if GeNeuro's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of GeNeuro's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as GeNeuro has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of GeNeuro's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess GeNeuro's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GeNeuro afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GeNeuro has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of GeNeuro's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jesús Martin-Garcia
COMPENSATION €779,756
AGE 54
TENURE AS CEO 3.3 years
CEO Bio

Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since January 01, 2016. Since 2004, he has been contributing to the companies created by Eclosion, serving as CEO in the early development stages, and later as Executive Chairman to help drive financial rounds and partnerships with pharma companies. He served as the Chief Executive Officer of GeNeuro SA. Mr. Martin-Garcia co-founded Le Shop SA in 1977. Since 1996, he has been active investing seed capital, supporting a number of start-ups in the Geneva region such as Silverwire. He started his career at the World Economic Foundation, and later at McKinsey & Co. focusing on Pharma and Food industries. He co-founded LeShop. He started a consulting career at McKinsey & Co. focusing on pharma and food industries. In 1993, Mr. Martin-Garcia served as the Founding Partner of Value Management Group. He served as Strategic Advisor to Eurpean incumbent Telcos for over a decade. Mr. Martin-Garcia serves as the Chairman of ArisGen SA. He serves as a Director of Eclosion SA and GenKyoTex S.A. He sits on the Board of the Harvard Business School Health Alumni Association. He obtained BS in Business Administration and a BA in law from the University of Geneva. He has entrepreneurial experience in managing successful start-ups. Mr. Martin-Garcia has a MS in Economics and a Master in Law from University of Geneva, and an MBA from Harvard Business School.

CEO Compensation
  • Jesús's compensation has been consistent with company performance over the past year.
  • Jesús's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the GeNeuro management team in years:

3.3
Average Tenure
54
Average Age
  • The tenure for the GeNeuro management team is about average.
Management Team

Jesús Martin-Garcia

TITLE
Chairman & CEO
COMPENSATION
€780K
AGE
54
TENURE
3.3 yrs

Miguel Payró

TITLE
Chief Financial Officer
AGE
53
TENURE
3.3 yrs

François Curtin

TITLE
Chief Operating Officer
AGE
53
TENURE
10.3 yrs

Hervé Perron

TITLE
Chief Scientific Officer
AGE
59

Robert Glanzman

TITLE
Chief Medical Officer
AGE
62
TENURE
3.3 yrs

Thomas Rückle

TITLE
Senior VP & Head of Pre-Clinical Development
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the GeNeuro board of directors in years:

3.8
Average Tenure
61
Average Age
  • The tenure for the GeNeuro board of directors is about average.
Board of Directors

Jesús Martin-Garcia

TITLE
Chairman & CEO
COMPENSATION
€780K
AGE
54
TENURE
13.2 yrs

Christophe Guichard

TITLE
Director
AGE
48
TENURE
3.4 yrs

Jean-Jacques Laborde

TITLE
Independent Director
AGE
72
TENURE
5.2 yrs

Michel Dubois

TITLE
Independent Director
COMPENSATION
€23K
AGE
75
TENURE
10.8 yrs

Gordon Francis

TITLE
Independent Director
COMPENSATION
€32K
AGE
68
TENURE
3.9 yrs

Giacomo Di Nepi

TITLE
Independent Director
COMPENSATION
€26K
AGE
65
TENURE
3.8 yrs

Eric Falcand

TITLE
Independent Director
AGE
56
TENURE
3.4 yrs

Marc Bonneville

TITLE
Independent Director
AGE
57
TENURE
3.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess GeNeuro's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GeNeuro has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurological disorders and autoimmune diseases. It develops GNbAC1, a monoclonal antibody that is in phase IIb of clinical development, as a treatment for multiple sclerosis. The company also focuses on developing its platform for other neurological diseases and autoimmune diseases, such as type 1 diabetes and chronic inflammatory demyelinating polyneuropathy. In addition, it develops therapeutics for inflammatory psychosis and amyotrophic lateral sclerosis. GeNeuro SA has a collaboration agreement with Laboratoires Servier to develop a medicine targeting a potential causal factor of multiple sclerosis; and U.S. National Institutes of Health (NIH) to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis. The company was founded in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Details
Name: GeNeuro SA
GEM
Exchange: DB
Founded: 2006
€61,126,175
14,588,586
Website: http://www.geneuro.ch
Address: GeNeuro SA
3, Chemin du Pré-Fleuri,
Plan-les-Ouates,
Geneva, 1228,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA GNRO Class C Common Shares Euronext Paris FR EUR 15. Apr 2016
OTCPK GNRR.F Class C Common Shares Pink Sheets LLC US USD 15. Apr 2016
DB GEM Class C Common Shares Deutsche Boerse AG DE EUR 15. Apr 2016
LSE 0RHK Class C Common Shares London Stock Exchange GB EUR 15. Apr 2016
Number of employees
Current staff
Staff numbers
28
GeNeuro employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:01
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2018/09/20
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.